This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


REDUCE MRSA Trial Awarded 2014 Distinguished Clinical Research Award by Clinical Research Forum


The Clinical Research Forum has selected the REDUCE MRSA trial as one of the winners of its third annual Top 10 Clinical Research Achievement Awards. The winning projects represent the outstanding examples of research projects that benefit the health and wellbeing of the general public.

The REDUCE MRSA trial found that using germ-killing soap and ointment on all intensive-care unit (ICU) patients can reduce bloodstream infections by up to 44 percent and significantly reduce the presence of methicillin-resistant Staphylococcus aureus (MRSA). A multidisciplinary team from the University of California, Irvine, Harvard Pilgrim Health Care Institute, Hospital Corporation of America (HCA) and the Centers for Disease Control and Prevention (CDC) carried out the study. A total of 74 adult ICUs and 74,256 patients were part of the study, making it the largest study on this topic to date.

For more information about the REDUCE MRSA trial, visit:

For more information about the Clinical Research Forum Top 10 Clinical Research Achievement Awards, visit:

comments powered by Disqus